

JosÃ© M Benito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5828055/publications.pdf>

Version: 2024-02-01

113
papers

4,260
citations

201674

27
h-index

118850

62
g-index

116
all docs

116
docs citations

116
times ranked

5502
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. <i>Cell Reports</i> , 2022, 38, 110235.	6.4	35
2	HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy. <i>Scientific Reports</i> , 2022, 12, 5095.	3.3	4
3	High Plasma sTNF-R1 Level Is Related to Loss of Natural HIV Control in Long-Term Elite Controllers. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 858872.	3.9	1
4	COVID-19 in people living with HIV: A multicenter case-series study. <i>International Journal of Infectious Diseases</i> , 2021, 102, 310-315.	3.3	41
5	Adherence to a Supplemented Mediterranean Diet Drives Changes in the Gut Microbiota of HIV-1-Infected Individuals. <i>Nutrients</i> , 2021, 13, 1141.	4.1	12
6	HIV-DNA content in pTfh cells is associated with residual viremia in elite controllers. <i>Aids</i> , 2021, 35, 393-398.	2.2	1
7	DBP rs7041 and DHCR7 rs3829251 are Linked to CD4+ Recovery in HIV Patients on Antiretroviral Therapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 773848.	3.5	0
8	NÍVEL DE ESTRESSE PERCEBIDO E INSTABILIDADE GENÉ"ICA ENTRE OS USUÁRIOS DE ACADEMIA. <i>Revista Jovens Pesquisadores</i> , 2021, 11, 03-11.	0.1	0
9	Persistent HIV controllers are more prone to spontaneously clear HCV: a retrospective cohort study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25607.	3.0	2
10	Elite controllers: A heterogeneous group of HIV-infected patients. <i>Virulence</i> , 2020, 11, 889-897.	4.4	17
11	Both HCV Infection and Elevated Liver Stiffness Significantly Impacts on Several Parameters of T-Cells Homeostasis in HIV-Infected Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2978.	2.4	2
12	Transcriptional signature of resting-memory CD4 T cells differentiates spontaneous from treatment-induced HIV control. <i>Journal of Molecular Medicine</i> , 2020, 98, 1093-1105.	3.9	3
13	Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients. <i>Vaccines</i> , 2020, 8, 323.	4.4	5
14	CD4 recovery is associated with genetic variation in IFN γ and IL19 genes. <i>Antiviral Research</i> , 2019, 170, 104577.	4.1	7
15	A high mucosal blocking score is associated with HIV protection. <i>Aids</i> , 2019, 33, 411-423.	2.2	4
16	IL7RA rs6897932 Polymorphism is Associated with Better CD4+ T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy. <i>Biomolecules</i> , 2019, 9, 233.	4.0	9
17	Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunosuppression. <i>PLoS ONE</i> , 2019, 14, e0214421.	2.5	11
18	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. <i>Scientific Reports</i> , 2019, 9, 5606.	3.3	22

#	ARTICLE	IF	CITATIONS
19	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 667-671.	3.1	14
20	Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control. <i>Journal of Infectious Diseases</i> , 2019, 219, 867-876.	4.0	23
21	A Knockout IFNL4 Variant Is Associated With Protection From Sexually Transmitted HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2019, 219, 772-776.	4.0	5
22	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. <i>BMC Medicine</i> , 2018, 16, 30.	5.5	19
23	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. <i>Journal of Virology</i> , 2018, 92, .	3.4	58
24	Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy. <i>Journal of Translational Medicine</i> , 2018, 16, 343.	4.4	6
25	Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients. <i>International Journal of Medical Sciences</i> , 2018, 15, 95-100.	2.5	2
26	CD32 Expression is not Associated to HIV-DNA content in CD4 cell subsets of individuals with Different Levels of HIV Control. <i>Scientific Reports</i> , 2018, 8, 15541.	3.3	13
27	High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control. <i>Frontiers in Immunology</i> , 2018, 9, 1399.	4.8	3
28	Peering into the HIV reservoir. <i>Reviews in Medical Virology</i> , 2018, 28, e1981.	8.3	21
29	Expression of PD-1 and Tim-3 markers of T-cell exhaustion is associated with CD4 dynamics during the course of untreated and treated HIV infection. <i>PLoS ONE</i> , 2018, 13, e0193829.	2.5	31
30	Both Hepatitis C Virus-Specific T Cell Responses and IL28B Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 278-286.	1.2	1
31	Peripheral T follicular helper Cells Make a Difference in HIV Reservoir Size between Elite Controllers and Patients on Successful cART. <i>Scientific Reports</i> , 2017, 7, 16799.	3.3	25
32	HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. <i>PLoS ONE</i> , 2017, 12, e0173943.	2.5	17
33	Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. <i>Aids</i> , 2016, 30, 553-562.	2.2	6
34	Rate and predictors of progression in elite and viremic HIV-1 controllers. <i>Aids</i> , 2016, 30, 1209-1220.	2.2	69
35	IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. <i>Liver International</i> , 2016, 36, 1258-1266.	3.9	5
36	Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfecting patients. <i>Journal of Translational Medicine</i> , 2016, 14, 257.	4.4	20

#	ARTICLE	IF	CITATIONS
37	Analysis of Non-AIDS-Defining Events in HIV Controllers. <i>Clinical Infectious Diseases</i> , 2016, 62, 1304-1309.	5.8	34
38	Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 226-231.	1.1	0
39	TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfecting patients. <i>Journal of Clinical Virology</i> , 2015, 65, 62-67.	3.1	6
40	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1833-1842.	3.0	56
41	PPAR β Pro12Ala Polymorphism Is Associated With Sustained Virological Response in HIV/HCV-Coinfected Patients Under HCV Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 113-119.	2.1	5
42	Immunological Function Restoration with Lopinavir/Ritonavir Versus Efavirenz Containing Regimens in HIV-Infected Patients: A Randomized Clinical Trial. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 425-433.	1.1	8
43	HIV gag-specific immune response mediated by double negative (CD3 ⁺ CD4 ⁺ CD8 ⁻) T cells in HIV-exposed seronegative individuals. <i>Journal of Medical Virology</i> , 2013, 85, 200-209.	5.0	11
44	Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. <i>European Journal of Immunology</i> , 2013, 43, 499-509.	2.9	16
45	The changing face of hepatitis C in the new era of direct-acting antivirals. <i>Antiviral Research</i> , 2013, 97, 36-40.	4.1	24
46	HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. <i>Aids</i> , 2013, 27, 1231-1238.	2.2	15
47	HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. <i>Aids</i> , 2013, 27, 1375-1385.	2.2	15
48	Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2616-2625.	3.0	14
49	A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 915-921.	3.0	4
50	Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. <i>Aids</i> , 2013, 27, 687-696.	2.2	10
51	Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 163-173.	2.2	12
52	Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715.	1.0	12
53	Short Communication: Does Interleukin-28B Single Nucleotide Polymorphisms Influence the Natural History of Hepatitis B?. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1262-1264.	1.1	13
54	Short Communication High Risk of Endothelial Dysfunction in HIV Individuals May Result from Deregulation of Circulating Endothelial Cells and Endothelial Progenitor Cells. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 656-659.	1.1	17

#	ARTICLE	IF	CITATIONS
55	Differences in Virological Response to Peginterferon- α Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 117-123.	2.1	12
56	Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. <i>Aids</i> , 2012, 26, 551-557.	2.2	9
57	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383.	4.0	31
58	Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012, 56, 788-794.	3.7	34
59	Different impact of IL28B polymorphisms on response to peginterferon- α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. <i>Journal of Clinical Virology</i> , 2012, 55, 58-61.	3.1	12
60	Impact of IL28B gene polymorphisms on interferon- γ plasma levels during pegylated interferon- α /ribavirin therapy for chronic hepatitis C in patients coinfecting with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1246-1249.	3.0	27
61	Elite Controllers Display Higher Activation on Central Memory CD8 T Cells Than HIV Patients Successfully on HAART. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 157-165.	1.1	26
62	The expansion ability but not the quality of HIV-specific CD8+ T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors. <i>Immunology</i> , 2011, 134, 305-313.	4.4	4
63	Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. <i>Aids</i> , 2011, 25, 269-271.	2.2	26
64	IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. <i>Aids</i> , 2011, 25, 1025-1033.	2.2	41
65	Response to: "Is the Study Power Enough to Say 'No Difference'?" by Geib et al. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, e37-e38.	2.1	0
66	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse. <i>Aids</i> , 2011, 25, 1131-1133.	2.2	20
67	An Additive Effect of Protective Host Genetic Factors Correlates With HIV Nonprogression Status. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 300-305.	2.1	24
68	Longitudinal Assessment of Interleukin 7 Plasma Levels in HIV-Infected Patients in the Absence of and Under Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 436-441.	2.1	5
69	Elevated TGF- β 1 levels might protect HCV/HIV-coinfected patients from liver fibrosis. <i>European Journal of Clinical Investigation</i> , 2011, 41, 70-76.	3.4	21
70	Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. <i>Journal of Infection</i> , 2011, 63, 382-390.	3.3	19
71	Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. <i>Clinical Immunology</i> , 2011, 139, 110-114.	3.2	60
72	Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1629-1636.	4.0	55

#	ARTICLE	IF	CITATIONS
73	Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2011, 53, 1291-1295.	5.8	16
74	HCV-Specific T-Cell Responses in HIV/Hepatitis C Virus-Coinfected Patients on Highly Active Antiretroviral Therapy Are Comparable to Those Observed in Hepatitis C Virus-Monoinfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 1-8.	2.1	21
75	Host factors involved in low susceptibility to HIV infection. <i>AIDS Reviews</i> , 2011, 13, 30-40.	1.0	11
76	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2010, 24, F23-F29.	2.2	184
77	Evolution of the Functional Profile of HIV-Specific CD8+ T Cells in Patients With Different Progression of HIV Infection Over 4 Years. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 29-38.	2.1	16
78	Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. <i>Clinical Infectious Diseases</i> , 2010, 51, 1209-1216.	5.8	56
79	Low-Level Exposure to HIV Induces Virus-Specific T Cell Responses and Immune Activation in Exposed HIV-Seronegative Individuals. <i>Journal of Immunology</i> , 2010, 185, 982-989.	0.8	38
80	Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to Disease Activity Score-28. <i>Autoimmunity</i> , 2009, 42, 636-645.	2.6	59
81	Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8 ⁺ T cells. <i>European Journal of Immunology</i> , 2008, 38, 1548-1558.	2.9	14
82	Short Communication:HIV Rebound after Discontinuation of Antiretroviral Therapy Increases and Expands HIV-Specific CD8+Responses But Has No Impact on Its Functionality. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1197-1201.	1.1	6
83	No Major Differences in the Functional Profile of HIV Gag and Nef-Specific CD8 ⁺ Responses between Long-Term Nonprogressors and Typical Progressors. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1185-1195.	1.1	13
84	Down-Regulation of Interleukin-7 Receptor (CD127) in HIV Infection Is Associated with T Cell Activation and Is a Main Factor Influencing Restoration of CD4 ⁺ Cells after Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2008, 198, 1466-1473.	4.0	58
85	Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years. <i>Aids</i> , 2008, 22, 1371-1374.	2.2	2
86	Escape Mutations in HIV Infection and its Impact on CD8+ T Cell Responses. <i>Current Molecular Medicine</i> , 2007, 7, 446-458.	1.3	11
87	Influence of Human T Cell Lymphotropic Virus Type 2 Coinfection on Virological and Immunological Parameters in HIV Type 1-Infected Patients. <i>Clinical Infectious Diseases</i> , 2007, 44, 105-110.	5.8	16
88	Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. <i>Aids</i> , 2007, 21, 583-588.	2.2	24
89	Impact of Ethnicity and HIV Type 1 Subtype on Response to First-Line Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 891-894.	1.1	16
90	Human T Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis in an HIV-Positive Patient Coinfected with Human T Lymphotropic Virus Type 2 Following Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2007, 45, e118-e120.	5.8	17

#	ARTICLE	IF	CITATIONS
91	Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4+ and CD8+ T-cell responses to hepatitis C virus. <i>Journal of Medical Virology</i> , 2007, 79, 503-510.	5.0	26
92	Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. <i>Journal of Medical Virology</i> , 2007, 79, 1040-1046.	5.0	43
93	Evolution of T-cell Responses to Hepatitis C Virus (HCV) during Pegylated Interferon plus Ribavirin treatment in HCV-Monoinfected and in HCV/HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007, 12, 459-468.	1.0	9
94	HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. <i>Blood</i> , 2006, 107, 4781-4789.	1.4	1,681
95	Coinfection with Hepatitis C Virus Increases Lymphocyte Apoptosis in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2006, 43, 1209-1212.	5.8	36
96	Degeneracy and Repertoire of the Human HIV-1 Gag p1777â€“85CTL Response. <i>Journal of Immunology</i> , 2006, 176, 6690-6701.	0.8	27
97	Immunological and Virological Effects of Structured Treatment Interruptions following Exposure to Hydroxyurea Plus Didanosine. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 734-743.	1.1	6
98	Impact of Gag Sequence Variability on Level, Phenotype, and Function of Anti-HIV Gag-Specific CD8+Cytotoxic T Lymphocytes in Untreated Chronically HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 884-892.	1.1	4
99	Differential Upregulation of CD38 on Different T-Cell Subsets May Influence the Ability to Reconstitute CD4+ T Cells Under Successful Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 373-381.	2.1	84
100	CD4+T Cell Recovery beyond the First Year of Complete Suppression of Viral Replication during Highly Active Antiretroviral Therapy Is Not Influenced by CD8+T Cell Activation. <i>Journal of Infectious Diseases</i> , 2005, 192, 2142-2146.	4.0	20
101	CD38 Expression on CD8 T Lymphocytes as a Marker of Residual Virus Replication in Chronically HIV-Infected Patients Receiving Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 227-233.	1.1	80
102	Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes. <i>Journal of Medical Virology</i> , 2004, 73, 350-361.	5.0	6
103	Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIVâ€“infected patients experiencing prolonged virologic failure. <i>Journal of Medical Virology</i> , 2004, 74, 21-28.	5.0	64
104	Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. <i>Aids</i> , 2004, 18, 1251-1261.	2.2	11
105	Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. <i>Aids</i> , 2004, 18, 1109-1116.	2.2	93
106	The role of CD8+ T-cell response in HIV infection. <i>AIDS Reviews</i> , 2004, 6, 79-88.	1.0	63
107	Virus Load and Cytolytic Responses in Human Immunodeficiency Virus Infection: What Is Cause and What Is Effect. <i>Journal of Infectious Diseases</i> , 2003, 188, 794-795.	4.0	2
108	Phenotype and Functional Characteristics of HIV-Specific Cytotoxic CD8+ T Cells in Chronically Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 255-266.	2.1	17

#	ARTICLE	IF	CITATIONS
109	Differences in Cellular Activation and Apoptosis in HIV-Infected Patients Receiving Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1379-1388.	1.1	34
110	Elevated levels of CD4+CD7 ⁺ T cells in HIV infection add to the prognostic value of low CD4 T cell levels and HIV-1-RNA quantification. <i>Aids</i> , 2001, 15, 2459-2460.	2.2	7
111	Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. <i>Aids</i> , 2000, 14, 2823-2829.	2.2	66
112	Quantitative Alterations of the Functionally Distinct Subsets of CD4 and CD8 T Lymphocytes in Asymptomatic HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 14, 128-135.	0.3	79
113	Serum β_2 -Microglobulin and Prediction of Progression to AIDS in HIV-Infected Injection Drug Users. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 8, 266-272.	0.3	10